[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371595-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371595-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-of-potential-of-targeted-sequencing-through-mutational-signature-simulation","Evaluation of potential of targeted sequencing through mutational signature simulation","","Background: Targeted sequencing is pivotal in cancer diagnosis, treatment selection, and monitoring, yet how well it reproduces whole-exome sequencing (WES) level mutational signatures remains uncertain. Methods: Simulation-based comparisons were performed using whole-exome sequencing mutation data and downsampled datasets for targeted gene sets across 13 cancer types, including additional similarity analyses with randomly downsampled data. Results: Targeted sequencing showed low correlation but high signature similarity versus WES; cancer gene sets required fewer genes than whole-genome sets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-of-potential-of-targeted-sequencing-through-mutational-signature-simulation/371595/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-of-potential-of-targeted-sequencing-through-mutational-signature-simulation/371595.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about targeted sequencing?","Question",{"text":63,"@type":64},"It evaluates how effectively targeted sequencing can reproduce mutational signatures at the whole-exome sequencing (WES) level.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the comparisons between WES and targeted sequencing performed?",{"text":68,"@type":64},"The study used simulation based on whole-exome mutation data, comparing correlation and similarity of mutational signatures between WES-level data and downsampled datasets for targeted gene sets across 13 cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"What gene set size requirements and cancer-type patterns were observed?",{"text":72,"@type":64},"Cancer-related gene random sets reached high similarity with about 200–400 genes, while whole-genome random sets required roughly 2–3 times more genes. Colorectal and lung cancers showed high similarity with fewer downsampled genes, whereas breast and prostate cancers required more.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371595,1790249093,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","OPEN ACCESS  \nCitation: Kodama K, Ling Y, Ichikawa H, Wakai T, Okuda S (2025) Evaluation of potential of targeted sequencing through mutational signature simulation. PLoS One 20(6):  \ne0326071. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0326071  \nEditor: Divijendra Natha Reddy Sirigiri, BMSCE: BMS College of Engineering, INDIA  \nReceived: October 10, 2024  \nAccepted: May 22, 2025  \nPublished: June 25, 2025  \nCopyright: © 2025 Kodama et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: This work was supported by funding from JSPS KAKENHI, Grant Numbers 22K19556 and 25K02714, awarded to TW. The funders had no role in study design, data  \nRESEARCH ARTICLE  \nEvaluation of potential of targeted sequencing through mutational signature simulation  \nKeisuke Kodama1, Yiwei Ling1,2, Hiroshi Ichikawa3, Toshifumi Wakai3, Shujiro Okuda1,2*  \n1 Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2 Medical AI Center, Niigata University School of Medicine, Niigata, Japan, 3 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan  \n* [okd@med.niigata-u.ac.jp](okd@med.niigata-u.ac.jp)  \nAbstract  \nBackground  \nTargeted sequencing is critical in cancer diagnosis, treatment selection, and monitoring. However, the effectiveness of these methods for reflecting whole-exome sequencing (WES)-level mutational signatures remains unclear. Therefore, we addressed this issue through simulation-based analysis to clarify how well targeted sequencing can reproduce WES-level mutational signatures.  \nMethods  \nWe compared the correlation and similarity of mutational signatures between whole-exome sequencing-level mutation data and downsampled data for gene sets targeted by each sequencing method in 13 cancer types. Additionally, a similarity analysis of the mutational signatures was conducted using randomly downsampled data.  \nResults  \nThe comparison between whole-exome sequencing and targeted sequencing showed a low correlation based on Pearson’s correlation coefficient but a high similarity based on the Dice similarity index. As a result of the downsampling of data with cancer-related genes and whole genes to evaluate similarity, the cancer-related gene random set showed high similarity when 200–400 genes were selected. However, the whole-genome random set required 2–3 times as many genes as the cancerrelated gene random set to show high similarity. Among cancer types, colorectal and lung cancers demonstrated high similarity with fewer downsampled genes, whereas breast and prostate cancers required more downsampled genes to achieve high similarity.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0326071](https://doi.org/10.1371/journal.pone.0326071) June 25, 2025 1 / 14  \ncollection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: NO authors have competing interests.  \nConclusion  \nThis study demonstrated that current clinically used targeted sequencing methods can reflect whole-exome sequencing-level mutational signatures. This suggests that considering the cancer type and average number of gene mutations in each patient when selecting targeted sequencing methods can lead to more effective treatment choices.  \nIntroduction  \nCancer is a gene-related disease, and driver mutations play critical roles in its development and progression [ 1 ,2] . Driver mutations are genetic alterations directly involved in the growth and survival of cancer cells, making them important targets for cancer diagnosis and treatment [3] . Because the key driver genes vary d","cbCaif6tlm5WzKJw","https://ap.wps.com/l/cbCaif6tlm5WzKJw","pdf",1733669,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What question does the study address about targeted sequencing?\",\"answer\":\"It evaluates how effectively targeted sequencing can reproduce mutational signatures at the whole-exome sequencing (WES) level.\"},{\"question\":\"How were the comparisons between WES and targeted sequencing performed?\",\"answer\":\"The study used simulation based on whole-exome mutation data, comparing correlation and similarity of mutational signatures between WES-level data and downsampled datasets for targeted gene sets across 13 cancer types.\"},{\"question\":\"What gene set size requirements and cancer-type patterns were observed?\",\"answer\":\"Cancer-related gene random sets reached high similarity with about 200–400 genes, while whole-genome random sets required roughly 2–3 times more genes. Colorectal and lung cancers showed high similarity with fewer downsampled genes, whereas breast and prostate cancers required more.\"}]","Evaluation of potential of targeted sequencing through mutational signature simulation | PDF",1790192410,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/620dc5b7e8978be1475d577fb447597a.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d912321ff907424baaf5e799fbcaf482.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c722abd872de1475ff5f4bbd1774f304.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e13bb5b1edf2443e7dbf7b20c575cabf.webp",980,1268]